Monocytes in Tumorigenesis and Tumor Immunotherapy

Chen, Xiaodie; Li, Yunqing; Xia, Houjun; Chen, Youhai H.

doi:10.3390/cells12131673

Cited by 15 publications

(10 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In ltration of M2 macrophages monocytes and neutrophils could promote tumor cell migration and invasion, and exert the function of inhibiting immunity, predicting a worse survival outcome [28][29][30] . This may be one of the reasons for the survival difference between the high-and low-risk groups.…”

Section: Discussionmentioning

confidence: 99%

Identification of a disulfidptosis-related genes signature for prognostic implication in ovarian cancer

Tang,

An,

Sun

2024

Preprint

View full text Add to dashboard Cite

Background: Ovarian cancer is an extremely deadly gynecological malignancy, with a 5-year survival rate below 30%. Additionally, disulfidptosis, a newly discovered type of cell death, has been found to be closely associated with the onset and progression of tumors. Methods: Disulfidptosis-related clusters were identified by consensus clustering. Univariate and multivariate Cox regression analyses were applied to construct a prognostic risk model. Patients were then divided into high- and low-risk groups. Gene mutation frequency, tumor microenvironment, and drug sensitivity analysis were performed between these two groups. Subsequently, a nomogram was constructed. Results: We identified 721 differentially expressed genes (DEGs) from two disulfidptosis-related clusters, and constructed a risk-prognosis signature. Analysis of the risk score revealed that compared to the high-risk group, the low-risk group had a better prognosis. Gene mutation frequency and tumor microenvironment analysis identified distinct characteristics between two risk groups. We also screened potential chemotherapy drugs that could sensitize ovarian cancer. Finally, the nomogram based on risk score and other clinical features showed a strong prognostic capability to predict overall survival (OS) for ovarian cancer patients. Conclusion: This study constructed a risk model related to disulfidptosis, which has a good prognostic value for ovarian cancer patients. The findings of this research provide novel insights into the understanding of ovarian cancer and could potentially lead to the development of new treatment strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of a disulfidptosis-related genes signature for prognostic implication in ovarian cancer

Tang,

An,

Sun

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…For example, within TME, increased activation of retinoic acid (RA) can drive intra-tumoral monocytes differentiated toward TAMs but shift away from differentiating into DCs via suppression of IRF4 49 ; ANXA1 promotes alternative macrophage polarization to enhance breast cancer growth 50 . Macrophages compete with DCs to degrade the tumor-associated antigens (TAA), preventing the initiation of antigen presentation and inducing immune tolerance 51 . Moreover, AnxA1, known to regulate the nuclear localization of EGFR, promotes T cell dysfunction by favoring the EGFR/STAT3 transcriptional activities in cancer cells, enhancing immune evasion and tumor progression 52 .…”

Section: Discussionmentioning

confidence: 99%

Single-cell Landscape of Malignant Transition: Unraveling Cancer Cell-of-Origin and Heterogeneous Tissue Microenvironment

Luo,

Liu,

Wen

et al. 2024

Preprint

View full text Add to dashboard Cite

Understanding disease progression and sophisticated tumor ecosystems is imperative for investigating tumorigenesis mechanisms and developing novel prevention strategies. Here, we dissected heterogeneous microenvironments during malignant transitions by leveraging data from 1396 samples spanning 13 major tissues. Within transitional stem-like subpopulations highly enriched in precancers and cancers, we identified 30 recurring cellular states strongly linked to malignancy, including hypoxia and epithelial senescence, revealing a high degree of plasticity in epithelial stem cells. By characterizing dynamics in stem-cell crosstalk with the microenvironment along the pseudotime axis, we found differential roles of ANXA1 at different stages of tumor development. In precancerous stages, reduced ANXA1 levels promoted monocyte differentiation toward M1 macrophages and inflammatory responses, whereas during malignant progression, upregulated ANXA1 fostered M2 macrophage polarization and cancer-associated fibroblast transformation by increasing TGF-β production. Our spatiotemporal analysis further provided insights into mechanisms responsible for immunosuppression and a potential target to control evolution of precancer and mitigate the risk for cancer development.

show abstract

“… 67 Phenotypically distinct subtypes of monocytes and macrophages have unique roles in the suppression or promotion of tumor development. 68 In patients with advanced pancreatic cancer, Soeda et al. reported an increase in the absolute number and percentage of circulating CD14 + monocytes after gemcitabine treatment.…”

Section: Immunomodulatory Effects Of Gemcitabine On Immune Cellsmentioning

confidence: 99%

The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer

Larson,

Doty,

Solheim

2024

Cancer Medicine

View full text Add to dashboard Cite

Although the development of immunotherapies has been revolutionary in the treatment of several cancers, many cancer types remain unresponsive to immune‐based treatment and are largely managed by chemotherapy drugs. However, chemotherapeutics are not infallible and are frequently rendered ineffective as resistance develops from prolonged exposure. Recent investigations have indicated that some chemotherapy drugs have additional functions beyond their normative cytotoxic capacity and are in fact immune‐modifying agents. Of the pharmaceuticals with identified immune‐editing properties, gemcitabine is well‐studied and of interest to clinicians and scientists alike. Gemcitabine is a chemotherapy drug approved for the treatment of multiple cancers, including breast, lung, pancreatic, and ovarian. Because of its broad applications, relatively low toxicity profile, and history as a favorable combinatory partner, there is promise in the recharacterization of gemcitabine in the context of the immune system. Such efforts may allow the identification of suitable immunotherapeutic combinations, wherein gemcitabine can be used as a priming agent to improve immunotherapy efficacy in traditionally insensitive cancers. This review looks to highlight documented immunomodulatory abilities of one of the most well‐known chemotherapy agents, gemcitabine, relating to its influence on cells and proteins of the immune system.

show abstract

Monocytes in Tumorigenesis and Tumor Immunotherapy

Cited by 15 publications

References 135 publications

Identification of a disulfidptosis-related genes signature for prognostic implication in ovarian cancer

Identification of a disulfidptosis-related genes signature for prognostic implication in ovarian cancer

Single-cell Landscape of Malignant Transition: Unraveling Cancer Cell-of-Origin and Heterogeneous Tissue Microenvironment

The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer

Contact Info

Product

Resources

About